2025-04-21 08:58:28 ET
DENVER, Colo., Apr 21, 2025 ( 247marketnews.com ) – Sunshine Biopharma (NASDAQ:SBFM) stated that its wholly owned Canadian subsidiary, Nora Pharma, launched Everolimus in Canada’s generic prescription drug market. Everolimus, a generic equivalent of Afinitor, is approved for treating advanced renal cell carcinoma, HER2-negative breast cancer in post-menopausal women, progressive neuroendocrine tumors of pancreatic, gastrointestinal, or lung origin, and subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Nora Pharma’s Everolimus is available in 2.5 mg, 5 mg, and 10 mg strengths, packaged in 30-tablet blister packs.
Dr. Steve Slilaty, Sunshine Biopharma’s CEO, commented, “Our presence in the industry is propelled by a relentless pursuit of progress. Through continued investment in cutting-edge technologies, breakthrough research, and strategic partnerships, we are advancing solutions that create lasting impact for patients.”
According to DATAINTELO, the global Everolimus market was valued at $2.5 billion in 2023 and is projected to grow at a 7.1% CAGR, reaching approximately $4.8 billion by 2032. The Canadian market, accounting for roughly 2.2% of the global share, is expected to grow at a 6.4% CAGR, per IQVIA Pharmafocus 2027.
The post Sunshine Biopharma Introduces Everolimus in Canada, Tapping into a $2.5 Billion Global Oncology Market appeared first on 24/7 MarketNews .
For further details see:
Sunshine Biopharma Introduces Everolimus in Canada, Tapping into a $2.5 Billion Global Oncology Market
